NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Ikonisys Develops Prenatal Diagnosis of Rare Genetic Disorders

Ikonisys is a medical devices company that has developed a combinatorial technological platform using molecular biology and imaging methodology for the detection of rare cells, including cancer cells, and for the prenatal diagnosis of rare genetic disorders. The company's proprietary cell-optics platform is an automated cell based diagnostic system that uses a highly sophisticated digital microscopy unit that can detect disease-specific cellular components and fluorescently labeled disease markers, enabling the detection and analysis of disease progression. The company has received FDA clearance for its fluorescent-based diagnostics of breast cancer, bladder cancer, and amniotic fluid prenatal genetic disorder screen.  Fluorescent light-based analysis and digital microscopy are two technologies that have significantly advanced the diagnostic field, enabling superior detection of scarce disease markers with high accuracy.

To continue reading, please Login or Join